Drug-drug combinations made simple
06 Nov 2013 - 06 Nov 2013 - Webinar
Date/Time: 6 November 2013, 4:00 PM CEST | 2:00 PM GMT | 10:00 AM EST | 7:00 AM PST
Drug screening for combinations or single agents can be demanding and tedious. At the Netherlands Cancer Institute Robotics and Screening Center (NRSC), potential drug combinations that either restore or enhance clinical response are selected based on large-scale genomic screening projects which combine genomic datasets including clinical data. The Institute’s HP D300 Digital Dispenser offers accurate, flexible and user-friendly experimental set-up for these combination studies, saving valuable time.
The NRSC uses an advanced technology platform to perform large-scale, high throughput screening projects with cell-based or biochemical assays. These screens enable researchers to identify novel targets for cancer therapy and understand the mechanism of action of novel drugs, as well as to identify resistance mechanisms and determine effective drug combinations for specific patient groups carrying defined genetic alterations.
In this presentation, the NRSC’s workflow for identification of drug combinations and follow-up drug synergy studies using the HP D300 will be presented.
About the speakers
Roderick L. Beijersbergen, Associate Professor Division of Molecular Carcinogenesis and Head NKI Robotics and Screening Center.
Pasi Halonen, Post-doc Division of Molecular Carcinogenesis and NKI Robotics and Screening Center
Jessica Merlino, Product Manager HP D300, Tecan